Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUR-928 in Alcoholic Hepatitis
NCT04563026Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of larsucosterol in alcoholic hepatitis (AH) (3 arms), sponsored by DURECT Corporation. Primary endpoint: Difference in 90-day mortality or liver transplant. Started Jan 2021; status: completed.
02
Drugs
larsucosterol
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT04563026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563026.